FindMyRecallSubscribe
Class II: temporary or reversible health riskTerminated

Regeneron Pharmaceuticals Eylea Recall

EYLEA, (aflibercept) Injection, For Intravitreal injection, 2 mg (0

Regeneron Pharmaceuticals Inc · Tarrytown, NY

Risk level
Class II
Reported by FDA
Jun 5, 2024
Recall ID
D-0531-2024
Check your lot numberHow we source this data

Summary

Regeneron Pharmaceuticals recalled Eylea starting May 15, 2024. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-0531-2024 on Jun 5, 2024. Reason: Lack of Assurance of Sterility: Complaints of syringe breakage. Status: Terminated.

Why it was recalled

Lack of Assurance of Sterility: Complaints of syringe breakage

Product description

EYLEA, (aflibercept) Injection, For Intravitreal injection, 2 mg (0.05mL of a 40mg/mL solution), Single-dose Pre-filled Glass Syringe, Rx only, Manufactured by: Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591, NDC 61755-005-01, NDC (sample lot) 61755-005-54

Lot numbers, UPCs & expiration codes

Lot # 8231500321, Exp. date Oct-24 8231500335, Exp. date Jan-25 8231500333, Exp. date Jan-25 8231500334, Exp. date Jan-25 8231500339, Exp. date Jan-25 8231500347, Exp. date Jan-25 8231500336, Exp. date Jan-25 8231500337, Exp. date Jan-25 8231500340, Exp. date Jan-25 8268700014 (sample lot) exp. date Jan-25

Where it was sold

USA nationwide.

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0531-2024
Classification
Class II
Status
Terminated
Recall initiated
May 15, 2024
FDA report date
Jun 5, 2024
Quantity
405,725 Prefilled syringes
Recall type
Voluntary: Firm initiated
Recalling firm
Regeneron Pharmaceuticals Inc

Original FDA data

Every field from FDA enforcement report D-0531-2024, exactly as published.

Show all FDA fields
City
Tarrytown
State
NY
Status
Terminated
Country
United States
Event ID
94646
Address
777 Old Saw Mill River Rd
Code information
Lot # 8231500321, Exp. date Oct-24 8231500335, Exp. date Jan-25 8231500333, Exp. date Jan-25 8231500334, Exp. date Jan-25 8231500339, Exp. date Jan-25 8231500347, Exp. date Jan-25 8231500336, Exp. date Jan-25 8231500337, Exp. date Jan-25 8231500340, Exp. date Jan-25 8268700014 (sample lot) exp. date Jan-25
Postal code
10591-6717
Report date
Jun 5, 2024
Product type
Drugs
Recall number
D-0531-2024
Classification
Class II
Recalling firm
Regeneron Pharmaceuticals Inc
Product quantity
405,725 Prefilled syringes
Termination date
Sep 25, 2025
Reason for recall
Lack of Assurance of Sterility: Complaints of syringe breakage
Voluntary / mandated
Voluntary: Firm initiated
Product description
EYLEA, (aflibercept) Injection, For Intravitreal injection, 2 mg (0.05mL of a 40mg/mL solution), Single-dose Pre-filled Glass Syringe, Rx only, Manufactured by: Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591, NDC 61755-005-01, NDC (sample lot) 61755-005-54
Distribution pattern
USA nationwide.
Recall initiation date
May 15, 2024
Initial firm notification
Letter
Center classification date
May 30, 2024

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0531-2024, published Jun 5, 2024. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls